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Is Sentinel Lymph Node Biopsy the Standard of Care for Cutaneous
Head and Neck Melanoma?
Cecelia E. Schmalbach, MD; Carol R. Bradford, MD
Objectives/Hypothesis: Sentinel lymph node biopsy (SLNB) is considered one of the most important melanoma
advancements to date. Since its inception in 1992, a plethora of data and associated controversies has emerged leading to the
question: Is SLNB considered the standard of care for head and neck (HN) cutaneous melanoma?
Study Design: English literature (1990–2014) review.
Methods: The PubMed database search was conducted using key terms “melanoma” and “sentinel node.” This review
included both dedicated HN SLNB studies and larger prospective SLNB studies, in which HN patients were included among
the cohort. Bibliography cross-referencing was conducted to ensure a comprehensive search.
Results: SLNB is safe and accurate in the HN region. Review of large prospective SLNB trials identified the pathologic
status of the SLN as the most important prognostic factor for recurrence and survival. Early lymphadenectomy following a
positive SLNB imparts a survival benefit.
Conclusions: Our review of the current literature suggests that SLNB is the standard of care for selected cases of HN
cutaneous melanoma. It is now incorporated into the American Joint Committee on Cancer staging system, the National Com-
prehensive Cancer Network practice guidelines, and numerous national and international consensus statements.
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INTRODUCTION
The incidence of cutaneous melanoma continues to
rise at epidemic proportions in the United States,1,2 with
137,990 new cases of melanoma estimated in 2014. This
rate has steadily increased by 2.8% per year since 1981.
The lifetime risk of developing melanoma will reach 1 in
50 Americans in 2015.3 One in four new cases present
before the age of 40; given this relatively young age,
melanoma is second only to adult leukemia in lost poten-
tial life years. Melanoma mortality has also risen by 3%
each year since 2004. As many as 9,710 Americans will
die from melanoma this year, approximately one patient
per hour.2 In 2010, the total direct cost of treating mela-
noma in the United States exceeded $2.3 billion.4
Regional metastasis remains the most important
prognostic factor for melanoma recurrence and survival.5
Up to 20% of patients presenting with a clinically and
radiographically N0 neck are harboring occult stage III
disease. In an effort to accurately stage patients and
identify individuals who may benefit from adjuvant ther-
apy, Donald Morton introduced sentinel lymph node
biopsy (SLNB) in 1992.6 This minimally invasive tech-
nique is regarded as one of the most important mela-
noma advancements to date.7 Over the past two
decades, a plethora of data and associated controversies
have emerged. This contemporary review investigates
the question: Is SLNB now the standard of care for head
and neck (HN) cutaneous melanoma?
RATIONALE BEHIND SLNB
Historically, patients with intermediate thickness
melanoma (1.0–3.9 mm) stage I and II disease under-
went elective neck dissection (END). Although initial
retrospective studies demonstrated a survival benefit,8
all four prospective, randomized trials failed to replicate
the overall survival benefit of END in the absence of
regional metastasis.9–12 Statistical power remains one
challenge in determining the survival benefits of early
detection of nodal disease.13 Only 20% of melanoma
patients presenting with localized stage I and II disease
actually harbor occult nodal metastasis and would bene-
fit from early removal; END is not expected to impart a
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survival benefit on the remaining 80% of stage I/II
patients with localized disease only. Detecting this small
difference requires extremely large clinical trials, with
enrollment numbering in the thousands. McMasters
et al. point out that the Intergroup Melanoma Surgical
Trial (IMST), World Health Organization (WHO), and
Mayo Clinic trials lacked adequate statistical power to
detect this small survival benefit.14
An additional challenge in identifying occult nodal
metastasis is the minute tumor burden harbored within
the node. In an END, entire at-risk nodal basins are
given to the pathologist for lymph node identification,
which is preformed manually via palpation. The nodes
are bivalved and stained with hematoxylin and eosin
(H&E). This technique can easily miss occult disease,
which can measure as small as 0.1 mm.3,15 In addition,
only 21% to 23% of positive sentinel lymph node (1SLN)
patients are diagnosed using traditional H&E stain-
ing.16,17 Current National Comprehensive Cancer Net-
work (NCCN) guidelines require only melanoma-specific
immunohistochemical staining (IHCS) alone within indi-
vidual cells to diagnose metastatic disease.18 Rigorous
pathology evaluation of all lymph nodes harvested in an
END specimen (to include serial microsectioning and
IHCS) is not feasible from a time or cost perspective.
SLNB TECHNIQUE
Because multiple prospective, randomized trials
failed to demonstrate an overall survival benefit for
patients undergoing END,8,10,11,19 the NCCN no longer
advocates routine END for melanoma.18 The procedure
has been replaced by SLNB, which represents a mini-
mally invasive, cost-effective, and efficient means of
staging and screening patients for regional metastasis.20
SLNB indications are summarized in Table I.
In brief, patients undergo preoperative injection of a
radioactive colloid. Lymphoscintigraphy is performed to
determine the number, location, and laterality of at-risk
draining nodal basins (Fig. 1). Fused single-photon emis-
sion computed tomography/computed tomography
(SPECT/CT) is emerging as a superior imaging modality
because of the increased anatomical three-dimensional
detail and improved resolution (Fig. 2). The largest pro-
spective study comparing SPECT/CT to planar lympho-
scintigraphy included 403 melanoma patients.21 SPECT/
CT was found to be superior, altering the surgical plan in
22% of cases. It yielded a higher number of 1SLNs per
patient (2.4 vs. 1.87; P<.001) as well as a higher meta-
static rate (0.34 vs. 0.21; P5.04). At a mean follow-up of
28.8 months, patients undergoing SLNB utilizing SPECT/
CT had a higher disease-free survival (DFS) compared to
the lymphoscintigraphy group (94% vs. 79%; P5.02). Mul-
tivariate analysis identified use of SPECT/CT as a factor
associated with DFS (hazard ratio [HR]5 4.11; P5.02).
Once under anesthesia, patients undergo intraoper-
ative lymphatic mapping with vital blue dye.6 Approxi-
mately 1 mL of dye is injected intradermally into the
four quadrants surrounding the primary melanoma
lesion. Studies consistently demonstrate increased SLNB
sensitivity when visual cues from blue dye are combined
with auditory cues from a radionucleotide.22,23
Unlike trunk and extremity melanomas, wide local
excision (WLE) of the HN primary is performed first,
because the close proximity of the tumor and draining
lymphatics creates radioactive “shine-through,” which
renders the gamma probe useless. Following WLE, at
risk nodal basins are evaluated for increased radioactiv-
ity using a handheld gamma probe (Fig. 3). By defini-
tion, a lymph node demonstrating 10% or greater
counters per minute compared to the hottest node ex
vivo is considered “sentinel.”24 A 1- to 3-cm incision is
TABLE I.
Sentinel Node Biopsy Indications for Stage I/II Cutaneous
Melanoma.
Breslow depth >1 mm
Breslow depth 0.76–1.0 mm in setting of adverse factors
Ulceration
Extensive regression to 1.0 mm
Young age
Mitotic rate 1/ mm2
Angiolymphatic invasion
Deep positive margin
Fig. 1. Lymphoscintigraphy planar imaging of a right auricular mel-
anoma draining to the right cervical chain. (A) Axial view. (B) Right
lateral view. Inj 5 Injection [Color figure can be viewed in the
online issue, which is available at www.laryngoscope.com.]
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made overlying the areas of increased radioactivity. A
preauricular incision and facial nerve monitoring are
recommended in the parotid region (Fig. 3).
Using a combination of the gamma probe and visual
cues from the blue dye, individual SLNs are identified
and sent separately for permanent histologic evaluation,
because a melanoma frozen sections carries a false nega-
tive rate of between 5% and 10%.25 The evaluation
includes serial microsectioning and H&E staining. Mela-
noma specific IHCS for S-100, melan-A (MART-1), and
HMB-45 are performed for all SLNs negative on H&E
staining. The mean number of SLNs per patient is 2.4,17
which allows for a more practical, thorough, and com-
plete histologic evaluation compared to an entire lymph-
adenectomy specimen.26 Patients with a 1SLN return to
the operating room within 2 weeks of diagnosis for defin-
itive therapeutic lymph node dissection (TLND); patients
with a negative biopsy are followed clinically.
The success of SLNB hinges upon communication and
a collaborative effort. An experienced nuclear medicine
team is imperative because inappropriate administration
of the radioactive tracer causes shine through. As noted
above, the pathologist plays an extremely critical role given
the tedious task of identifying micrometastatic disease.
The referring dermatology team is vital in working up and
identifying appropriate SLNB candidates. Last, the sur-
geon requires experience in the SLNB technique. Morton
et al. prospectively identified a 55-case learning curve to
achieve at least 95% accuracy with SLNB.25
SUPPORTING EVIDENCE FOR SLNB
SLNB is considered standard of care in 2014 for
eight reasons.
Fig. 2. (A) Single-photon emission
computed tomography/computed
tomography (SPECT/CT) of right
auricular melanoma. (B) SPECT/CT
of the radioactive colloid injection
site surrounding auricular melanoma.
(C) SPECT/CT demonstrating lym-
phatic draining to a right level II sen-
tinel node superficial to the internal
jugular vein. Note the increased ana-
tomic detail compared to lympho-
scintigraphy in Figure 1. [Color figure
can be viewed in the online issue,
which is available at www.laryngo-
scope.com.]
Fig. 3. Handheld gamma probe used to identify increased area of
radioactivity associated with sentinel node. Note the use of a pre-
auricular incision for sentinel lymph node biopsy in the parotid
nodal basin. [Color figure can be viewed in the online issue, which
is available at www.laryngoscope.com.]
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First, the pathologic status of the SLN is the most
important prognostic factor for melanoma recurrence
and survival. In 1999, Gershenwald et al. conducted a
multivariate analysis on 580 stage I/II melanoma
patients (8.1% HN subsite) and found the SLN status
(positive or negative for micrometastasis) to be the most
significant prognostic factor for both DFS (HR53.41;
P<.00001) and melanoma specific survival (MSS)
(HR56.53; P<.0001).27 Table II lists other recognized
prognostic variables for comparison. The largest single-
institution SLNB study dedicated to HN melanoma pro-
spectively followed 353 patients and reported similar
results.17 Best multivariate model analyses revealed
1SLN status as the strongest factor associated with
decreased DFS and MSS (Table III). At 10 years follow-
up, the Multicenter Selective Lymphadenectomy Trial-1
(MSLT-1) trial confirmed sentinel node status as the
strongest predictor for disease recurrence and death.28
Second, lymph node tumor burden (microscopic vs.
macroscopic disease) is the second most important prog-
nostic factor following number of nodal metastasis for
stage III melanoma. A prospective analysis of 1,429 mel-
anoma patients (trunk, extremity, and HN subsites)
with lymph node metastasis identified an improved 5-
year survival rate for patients presenting with clinically
negative but pathologically positive nodal disease, com-
pared to patients with both clinically and pathologically
palpable nodal disease (P<.0001).29 These data were so
compelling that the American Joint Committee on Can-
cer (AJCC) incorporated SLN status into the revised
2002 sixth edition cancer staging system.30 This utiliza-
tion of SLNB for staging was validated in the follow-up
multi-institutional prospective trial of 3,307 stage III
melanoma patients.5 Cox multivariate analysis identified
the number of metastatic lymph nodes, tumor burden
(microscopic vs. macroscopic) at the time of staging,
tumor ulceration, and depth of invasion as the most
important independent predictors of survival (all P
values< .001).
Third, SLNB remains the most specific and sensi-
tive means for regional staging. It is important to recog-
nize that, even in 2014, the SLN technique remains a
staging tool no different than magnetic resonance imag-
ing, computed tomography, and positron emission tomog-
raphy. Cross-sectional imaging using traditional
radiographic modalities only identifies 0.5% to 3.7% of
occult stage III melanoma cases.31–34 Given the minute
tumor volume in a 1SLN, it is unsurprising that serial
sectioning with melanoma IHCS carries greater
sensitivity.
Fourth, SLNB is now incorporated into the current
NCCN guidelines.18 Given the above-noted prognostic
significance of a 1SLN, as well as the inability to reli-
ably identify occult nodal disease with radiographic
imaging alone, the NCCN panel has incorporated SLNB
into the treatment algorithm. Patients meeting criteria
listed in Table I warrant a discussion on the utility of
SLNB.
Fifth, staging with SLNB imparts a survival bene-
fit. The MSLT-1 trial28 commenced in 1994 to determine
if immediate completion lymphadenectomy yields a sur-
vival benefit compared to observation. This study
included trunk, extremity, and HN cutaneous melanoma
patients. A total of 2,001 stage I/II melanoma patients
were randomized to WLE with observation and delayed
lymphadenectomy for nodal recurrence versus
WLE1SLNB with immediate lymphadenectomy for
micrometastatic disease (Fig. 4). A 10-year follow-up
demonstrated that SLNB correctly determined the path-
ologic nodal stage in 96% of cases. Patients with inter-
mediate (1.20–3.5 mm) and thick (>3.5 mm) melanomas
in the WLE1SLN group demonstrated an improved 10-
year DFS compared to their observation counterparts.
Although a significant treatment-related difference in
MSS was not identified among the entire cohort, this
finding was expected given that only 20% of study
patients harbored regional disease and would benefit
from intervention. Subgroup analysis of patients with
nodal disease confirmed an improved MSS in the
TABLE II.
Multivariate Analysis of Prognostic Factors Impacting Melanoma Survival.27
Disease-Free Survival Melanoma-Specific Survival
Prognostic factor HR 95% CI P Value HR 95% CI P Value
Tumor thickness 1.21 1.11-1.31 <.00001 1.23 1.10-1.38 .0004
Ulceration 1.73 1.13-2.65 .01 1.62 0.85-3.08 .14
SLN status 3.41 2.25-5.17 <.00001 6.53 3.39-12.58 <.00001
CI5 confidence interval; HR5hazard ratio; SLN5 sentinel lymph node.
TABLE III.
Best Multivariate Model for Melanoma Survival.17
Prognostic Factor HR 95% CI P Value
Disease-free survival
Breslow depth 1.15 1.04-1.27 .0049
Age 1.03 1.02-1.04 <.0001
1SLN 4.23 2.73-6.54 <.0001
Melanoma-specific survival
Ulceration 2.05 1.22-3.45 .0069
Age 1.03 1.03-1.05 <.0001
1SLN 3.33 1.99-5.58 <.0001
CI5 confidence interval; HR5hazard ratio; 1SLN5positive sentinel
lymph node.
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WLE1SLN group compared to observation (62% vs.
41.5%; P5.006). This treatment-related difference was
unique to patients with intermediate-thickness melano-
mas but not thick melanomas. These long awaited
MSLT-1 results demonstrate that early lymphadenec-
tomy following a positive SLNB decreases nodal recur-
rence, distant metastasis, and death from melanoma for
intermediate- thickness melanoma patients with occult
regional disease.
Sixth, the American Society of Clinical Oncology
and the Society of Surgical Oncology recently published
updated clinical practice guidelines recommending the
use of SLNB for melanoma.35 SLNB is recommended for
all patients meeting the criteria listed in Table I, regard-
less of the primary lesion. Their recommendation fol-
lowed an evidence-based systematic review of the
literature yielding 73 studies.
Seventh, The WHO issued a statement that SLNB
is the standard of care for melanoma.36 This position
statement was issued in 1999, and SLNB was recognized
as “the starting point for future policies on surgery and
adjuvant treatment strategies.”
Eighth, SLNB allows for accurate staging and iden-
tification of a homogeneous population of patients to
enroll in clinical trials.14 Stage III melanoma is a hetero-
geneous category with broad 5-year survival rates, rang-
ing from 78% for patients with one positive
micrometastatic node (stage IIIA) to a dismal 40% for
patients with three or more positive nodes (stage IIIC).5
SLNB remains the most accurate means of regional
staging, which is imperative to identify a homogeneous
population of patients with like outcomes. Without accu-
rate pathologic staging, stratification is impossible, and
the result of clinical trials would be difficult to interpret.
SLNB “CONTROVERSIES”
Feasibility in the HN Region
A 34% discordance between clinical prediction of
HN lymphatic drainage and lymphoscintigraphy find-
ings in 97 melanoma cases raised concern about the reli-
ability of SLNB in the watershed lymphatics of the HN
region.37 Concerns for damage to surrounding vital
structures, such as the great vessels, facial nerve, and
spinal accessory nerve, also limited popularity.38
Throughout the past two decades, studies have consis-
tently demonstrated that SLNB can be accurately per-
formed in cervical nodal basins without significant risk
to the cranial nerves and great vessels.39–42 The largest
HN SLNB prospective study identified in 352 of 353
cases (99.7%) no reported permanent facial nerve, cra-
nial nerve, or vascular damage. Sixty-nine of 353
patients (19.6%) had a 1SLN biopsy.17 This 19.6% posi-
tivity rate mirrors the results achieved in other ana-
tomic sites such as the trunk and extremities.10,43 At a
mean follow-up of 48 months, 12 of 283 negative SLN
patients where locally free of disease but developed
regional recurrence within a previously mapped nodal
basin, yielding a false-negative rate of 14.8% (12 false
negatives/12 false negatives1 69 true positives). The
negative predictive value of 95.8% and false rate of omis-
sion of 4.2% mirrors that of trunk and extremity mela-
noma, thus demonstrating feasibility of SLNB in the HN
region.
SLNB Safety in the Parotid Basin
Overall, 25% to 30% of HN cutaneous melanomas
drain to the parotid nodal basin,37,39 where injury to the
facial nerve has led some surgeons to advocate for super-
ficial parotidectomy over SLNB.38 Numerous studies
have demonstrated that SLNB can be reliably and safely
performed within the parotid nodal basin, especially
when utilizing continuous facial nerve monitoring.39,44,45
Inflammation and fibrosis from SLNB was thought to
place the facial nerve at increased risk when a therapeu-
tic superficial parotidectomy was required after a
1SLNB.38 Erman et al. reported preservation of facial
nerve function in all patients undergoing therapeutic
superficial parotidectomy following a positive SLNB.17
In-transit Metastasis
Authors have suggested that SLNB increases the
risk of in-transit metastasis (ITM), which is defined as
intralymphatic tumor dissemination within cutaneous or
subcutaneous tissue located between the primary lesion
and draining nodal basin.46–48 ITM presents a therapeu-
tic challenge and carries a poor prognosis.30 Original
reports citing increased ITM following SLNB often
entailed pooled data from small cohorts, and failed to
control for important prognostic factors such as tumor
thickness and ulceration.46,49 A follow-up prospective
review comparing 4,412 patients undergoing WLE, WLE
with SLNB, and elective lymph node dissection (ELND)
identified a correlation between ITM and increasing Bre-
slow depth, Clark level, and T stage.50 A statistically sig-
nificant difference between ITM and tumor recurrence
was not found among the treatment groups, once adjust-
ment was made for T-stage, age, sex, tumor thickness,
and site. Additional studies have concluded that it is the
tumor biology, as opposed to the surgical procedure
(SLNB, ELND), that dictates melanoma metastatic
behavior.46,51 Finally, a correlation between ITM and
Fig. 4. Randomization schema for multicenter selective lymphade-
nectomy trial. SLN5 sentinel lymph node; SLNB5 sentinel lymph
node biopsy; TLND5 therapeutic lymph node dissection. [Color
figure can be viewed in the online issue, which is available at
www.laryngoscope.com.]
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SLNB was not reported with MSLT-1, thus negating this
concern.25
FUTURE SLNB ENDEAVORS
Future SLNB research endeavors hold exciting
promise. In an effort to investigate the therapeutic
potential of SLNB, recent research efforts focus on iden-
tifying markers of both the primary lesion and SLN,
which are predictive of tumor remaining in non-
SLNs.52–54 Such markers may allow identification of a
subset of 1SLN patients who do not require formal
TLND. Unfortunately, current studies have failed to
identify a consistent and 100% accurate marker. For this
reason, the ongoing MSLT-II trial is designed to investi-
gate the indications for TLND following a 1SLNB.25 It
will determine whether immediate TLND provides a sur-
vival benefit over postoperative, diligent, ultrasono-
graphic monitoring of the draining nodal basins. The
European Organization for Research and Treatment
(EORTC) Melanoma Group MINITUB trial is also
designed to determine if patients with minimal 1SLN
tumor burden require TLND. Until the results of these
trials are available, TLND following 1SLNB remains
the standard of care.7,18,35
Molecular staging of melanoma has also gained
increased interest. Reverse transcriptase polymerase
chain reaction (RT-PCR) analysis of SLNs for melanoma-
associated genes such as MART-1, tyrosinase, and
tyrosinase-related protein 2 (TRP-2) have proven helpful
in identifying a subset of patients harboring occult nodal
disease at a submicroscopic level that cannot be detected
with traditional IHCS.55–57 In one study, 30% (49 of 162)
of patients with at least one melanoma marker identified
with RT-PCR experienced an increased rate of recur-
rence despite a negative SLNB.58 Currently, RT-PCR
carries a high false-positive rate attributed to the inabil-
ity to differentiate melanoma cells from occult benign
nevus cells. Through future research efforts, molecular
staging may prove helpful in the identification of a sub-
set of high-risk melanoma patients who develop nodal or
distant metastases despite presentation with a thin pri-
mary tumor.59
Near-infrared (NIR) fluorescence utilizing indocya-
nine green (ICG) provides the surgeon real-time transcu-
taneous visualization of superficial draining lymphatic
channels.60 The fluorescence signal potentially aids the
pathologist in preparing and analyzing SLNs.61,62 Opti-
cal imaging with ICG as a lymphatic tracer has been
successfully applied in various cancers.63 Four dedicated
cutaneous carcinoma studies have been published.64–67
The investigations are limited to case reports and small
series for a total of 42 patients. Although NIR fluores-
cence has outperformed traditional blue dye in several
SLN clinical trials,62,68,69 tissue depth and large body
mass index remains the rate-limiting factor. A hybrid
tracer combining ICG with 99mTc-radioactive colloid has
been introduced to increase depth of detection and
lengthen retention time of the tracer.69 The application
of SLN optical imaging remains investigational at pres-
ent but is promising.
Application in Thin Melanomas
The majority of SLNB studies focus upon intermedi-
ate thickness melanomas, which carry approximately a
20% rate of occult nodal metastasis. The utility of this
technique in thin melanomas remains to be determined.
Morton et al. could not draw meaningful conclusions
from the 340 MSLT-1 patients with thin melanomas
measuring <1.20 mm invasion.28 A meta-analysis of
SLN positivity in thin melanomas 1 mm identifies a
pooled occult nodal disease rate of 5.6%.70 Consistent
clinical and histopathologic criteria to reliability identify
this small at-risk thin melanoma populaiton is lacking.
Future studies are required and will need to balance
benefit with cost and associated morbidity.
CONCLUSION
Regional metastasis remains the most important
prognostic factor in melanoma. Decreased melanoma
mortality ultimately hinges upon accurate staging, espe-
cially because the majority of stage III melanoma
patients are now diagnosed with micrometastatic as
opposed to macrometastatic disease.71 SLNB represents
a minimally invasive, cost-effective, and efficient means
of staging and screening patients for regional metasta-
sis.20 It is now considered the standard of care for inter-
mediate thickness melanomas as supported by its
incorporation into the AJCC staging system,5 NCCN
guidelines,18 and numerous oncology consensus state-
ments.35,72–74
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